Danaher Corporation (NYSE: DHR) and Boston Scientific Corporation (NYSE:BSX) are both large-cap multi-sector conglomerates companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Dividends

Danaher Corporation pays an annual dividend of $0.56 per share and has a dividend yield of 0.6%. Boston Scientific Corporation does not pay a dividend. Danaher Corporation pays out 17.8% of its earnings in the form of a dividend. Danaher Corporation has raised its dividend for 3 consecutive years.

Insider and Institutional Ownership

75.7% of Danaher Corporation shares are held by institutional investors. Comparatively, 90.4% of Boston Scientific Corporation shares are held by institutional investors. 12.2% of Danaher Corporation shares are held by company insiders. Comparatively, 0.7% of Boston Scientific Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Danaher Corporation and Boston Scientific Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Danaher Corporation $17.43 billion 3.46 $4.16 billion $3.14 27.67
Boston Scientific Corporation $8.71 billion 4.61 $2.31 billion $0.58 50.41

Danaher Corporation has higher revenue and earnings than Boston Scientific Corporation. Danaher Corporation is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Danaher Corporation and Boston Scientific Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Danaher Corporation 0 4 11 0 2.73
Boston Scientific Corporation 0 4 13 0 2.76

Danaher Corporation presently has a consensus price target of $91.86, indicating a potential upside of 5.74%. Boston Scientific Corporation has a consensus price target of $30.46, indicating a potential upside of 4.19%. Given Danaher Corporation’s higher possible upside, analysts plainly believe Danaher Corporation is more favorable than Boston Scientific Corporation.

Profitability

This table compares Danaher Corporation and Boston Scientific Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Danaher Corporation 12.63% 11.15% 5.95%
Boston Scientific Corporation 9.04% 23.62% 9.01%

Risk and Volatility

Danaher Corporation has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Boston Scientific Corporation has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Summary

Boston Scientific Corporation beats Danaher Corporation on 9 of the 17 factors compared between the two stocks.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. As of December 31, 2016, Danaher’s research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.